Head-to-head evidence
GSK5784283 vs Tezepelumab (APFS)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
GSK5784283
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07712393 (registry estimate)
Tezepelumab (APFS)
Marketed by AstraZeneca
NCT03968978 · Phase 3 · completed
The study randomized 216 participants 1:1 to two active device types but was open-label, with no placebo or blinded control. Its primary endpoint was successful device administration rather than a clinical asthma outcome, and although arm-specific results were posted, the registry does not state whether the between-device comparison was statistically significant.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GSK5784283's landscape · Tezepelumab (APFS)'s landscape